Clinical trial
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT05844956 is registered in ClinicalTrials.gov with Dizal Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
- Lead sponsor
- Dizal Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 1, 2022
- Completion date
- February 29, 2024
- Enrollment
- 17 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.